Articles On Adalta (ASX:1AD)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead’s Ashtyn Hiron sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news. AdAlta announced a partnership with venture capital firm  SYNthesis BioVentur...

Special Report: AdAlta and SYNthesis BioVentures Fund (SYNBV) are collaborating to form AdCella, a jointly owned entity aimed at facilitating the entry of innovative cellular immunotherapies from Asia into western regulated markets, leverag...

It’s been a tough couple of years for ASX health care with challenging economic conditions including steep interest rates rises to combat soaring inflation hitting the sector like a nasty dose of influenza. Furthermore, a frenzy around the...

  Tim Oldham – CEO & Managing Director – AdAlta (ASX:1AD) is a clinical-stage biotechnology company using its i-body platform to discover and develop next-generation protein therapeutics addressing drug targets that are challenging for...

ASX health sector rises in line with broader markets in the past five days  AdAlta reports positive Phase 1 extension trial results of AD-214 into IPF Mach7 signs $3.1 million, three-year renewal contract with Penn State Health Morgans h...

AdAlta (ASX:1AD) has announced results from its Phase 1 extension study of lead asset AD-214 in development for fibrotic diseases, including the debilitating and fatal disease Idiopathic Pulmonary Fibrosis.

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Local markets end slightly higher IT Sector slumps 1.2pc Small Caps led by AT1   The ASX 200 traded sideways again today, closing the day +0.1% higher as gains in Financials and Real Estate were offset by losses in Tech and Mining stocks....

Phase I extension study of AD-214 tested the target Phase II dose of AD-214 in healthy volunteers AdAlta says the findings positively answer key partner questions and support progressing AD-214 Phase II clinical studies in Idiopathic Pulmo...

Top-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the treatment of fibrotic disease have established the safety, tolerability and bioavailability of a target dose for planned Phase II clinical studi...

06 Mar 2024 - A snapshot of the stocks on the move, featuring Atomo Diagnostics (ASX:AT1), AdAlta (ASX:1AD) and Aruma Resources (ASX:AAJ).

  To register for Friday's webinar click here. Atomo Diagnostics (ASX:AT1) has announced securing purchase orders from Viatris Healthcare Pty Ltd for approximately AUD $970,000 worth of HIV Self-Tests, manufactured by Atomo under the Mylan...

Atomo jumps 90pc after reporting a significant sales order AdAlta up 20pc after revealing key results from Phase 1 study Race Oncology’s drug shows potent anticancer activity    Atomo up 90pc on HIV kit sales Atomo Diagnostics (ASX:AT1)...

Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  ASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small cap winners led by American Rare Earths and Appen   The benchmark was shot through the heart by CSL this morning leaving everything else in...

AdAlta AD-214 Phase I extension study results forecast for release at end of February Results crucial as AdAlta looks to advance partnering discussions to take asset to Phase II trial 1AD’s trademarked i-body platform advancing next genera...

  Tim Oldham, CEO and Managing Director, AdAlta (ASX:1AD) is a clinical stage biotechnology company using its i-body platform to discover and develop next generation protein therapeutics addressing drug targets that are challenging fot othe...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

AdAlta’s AD-214 Phase 1 extension study interim data reinforce safety profile and dose selection Company preparing for partnering and Phase 2 trial of AD-214 into Idiopathic Pulmonary Fibrosis In the US ~40,000 people die annually from Id...

PainChek’s European patent HeraMed signs deal with Telstra AdAlta announced interim Phase 1 results Avita lowers 2023 guidance PainChek’s European patent application accepted PainChek (ASX: PCK) announced that the European Patent Office...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

ASX200 closes +1.13% higher Property stocks, Industrials and IT Sector gain more than 2% Small caps led by takeover target MCM   The Australian sharemarket has ended the first week of November with another stout performance, momentarily a...

AdAlta (ASX:1AD), a clinical-stage company developing novel protein and cell therapeutic products from its i-body platform, has announced that all healthy volunteers in its AD-214 Phase 1 extension study have now successfully receiv...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Aussie shares set to track Wall Street lower at the open CPI report will be the main focus this week What are the common mistakes for stock traders    Australian shares are poised to track Wall Street and open lower this morning. At 8am A...

Clinical stage drug discovery company AdAlta (ASX: 1AD) has completed the recruitment of healthy volunteers to its Phase I extension study of lead candidate AD-214 to treat debilitating and fatal scarring diseases including idiopathic pulmo...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

  ASX 200, Small Ords and Emerging Co’s indices all close -0.8% in the red Only the Energy Sector finds some green Small caps led by teeny-tiny energy minnow CCE The Australian sharemarket dropped on Wednesday, dragged down by miners and...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Mesoblast plunged over 50pc after FDA response AdAlta progresses on Phase 1 extension study ResMed down 10pc on falling margins Mesoblast asked to provide more data by FDA Regenerative medicine company Mesoblast (ASX:MSB) was hammered do...

Futures predict the ASX will again open in the red as US earnings season continues on and US job data is soon to be revealed. Back home, local traders are holding out for the RBA’s latest statement on its monetary policy decision made th...

Local shares are poised to extend losses on Friday Tech titans Apple, Amazon and Atlassian reported their quarterlies August could live up to its “very boring” historical reputation for the stock market   The ASX 200 is set to open lower...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

AdAlta (ASX:1AD) has released new data on the potential efficacy of AD-214 in humans with Idiopathic Pulmonary Fibrosis and other fibrotic diseases.

The ASX has ended the final day of the trading week firmly in the red. All sectors were down with IT stocks taking the biggest hit – falling more than two per cent. Today findings were released from the Royal Commission into Centrelin...

The S&P ASX 200 closes 1.69% lower setting new 50-day low, with Emerging Companies index also falling Golden Deeps uncovers in-demand germanium and gallium at Nosib vanadium-copper-lead-silver discovery AdAlta announces new data pointi...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Amid the bombed-out biotech sector, early-stage developers of a new cancer immunotherapy have caught the eye of investors after some promising clinical news. These companies are working on so-called CAR-T therapies, which work by ‘superchar...